Safety & Harm Reduction

Cannabis: Cutting Back and Getting Help

The choice is not between carrying on as you are and stopping for good. Researchers now treat using less as a meaningful result in its own right. This guide covers lowering risk if you keep using, what professional help involves and how well it works, what medication can and cannot do, and when cannabis becomes a medical matter.

Important

This guide is for educational purposes only. It is not medical advice. Always consult healthcare professionals before making decisions about substance use. If you are in crisis, call 988 (Suicide & Crisis Lifeline) or the Fireside Project at 62-FIRESIDE.

Using less counts

In studies of people getting help, using on fewer days went with better quality of life, and with less anxiety, low mood and poor sleep. Medication trials have often been judged failures on abstinence alone, even though reductions in use were frequent and went with feeling better.

  • Fewer days of use is the change most consistently linked with feeling better
  • In one study, cutting the amount used without cutting the number of days made no measurable difference to quality of life

Sources: Brezing et al. 2018; Hser et al. 2017; Atkin et al. 2026

Lowering risk if you keep using

An international guideline, updated in 2022, sets out how people who use cannabis can lower their risk of harm. Its main points are below.

  • The later you start, the lower the risk; adolescence is the most vulnerable period
  • Choose lower-THC products
  • Avoid frequent or intensive use
  • Choose a route other than smoking
  • Take particular care if you are pregnant, driving, older, or have another health condition
  • Use legal, regulated products where they are available

Sources: Fischer et al. 2022

What professional help looks like

The best-supported approach combines cognitive-behavioral therapy with motivational enhancement, a counseling style that builds on your own reasons for change. The evidence is real and its certainty is low.

  • Across 22 trials with 3,304 people, this combination made abstinence more likely than no active treatment
  • More sessions work better than fewer: nine sessions outperformed two in a trial of 450 adults, and two outperformed waiting
  • About seven in ten people complete a course
  • Help reliably reduces how much people use; lasting abstinence is uncommon, as it is for other substances
  • Rewards for verified abstinence may add to the effect

Sources: Halicka et al. 2025; Gates et al. 2016; Marijuana Treatment Project Research Group 2004; Connor et al. 2021; Lima et al. 2024

Medication

No medication is approved for cannabis use disorder or for cannabis withdrawal. A 2025 review of 37 trials concluded that every medication tested should still be considered experimental.

  • No medication tested made stopping completely more likely
  • In single trials, CBD and a prescription THC and CBD spray reduced how often people used; neither has been shown to help people stop
  • N-acetylcysteine, a supplement sometimes suggested for quitting, did not help adults in a trial of 302 people
  • A clinician may treat a specific symptom, such as poor sleep or nausea, for a short time

Sources: Spiga et al. 2025; Connor et al. 2022; Freeman et al. 2020; Lintzeris et al. 2019; Gray et al. 2017; Kondo et al. 2020

Apps and self-guided programs

Digital programs have a modest effect. In young adults they reduced use by about seven days a month at three months. For digital treatment programs, the effect is small and fades.

  • A self-guided program can support a change you have decided to make
  • It is not a substitute for professional help when use has become hard to control
  • BTYBD is education. It is not a treatment program

Sources: Côté et al. 2024; Boumparis et al. 2019; Fontana et al. 2025

When it is a medical matter

Some situations need a clinician, and a few need one urgently.

  • Repeated vomiting: bouts of severe nausea and vomiting in a regular user, eased by hot showers or baths, point to cannabinoid hyperemesis syndrome. It stops when cannabis stops. Get medical care for repeated vomiting
  • Psychosis: heavy use and stronger products are linked with higher odds of psychosis. Paranoia, or seeing or hearing things that are not there, needs urgent help
  • Other conditions: with another mental health condition, or other substance use, plan any change with a clinician
  • Pregnancy: obstetric guidance links cannabis use in pregnancy with preterm birth and low birth weight. Talk to your obstetric clinician

Sources: Sorensen et al. 2017; Habboushe et al. 2018; Marconi et al. 2016; Di Forti et al. 2019; Chesney et al. 2025; Connor et al. 2022; American College of Obstetricians and Gynecologists 2025

Helping someone else

For family and partners, a structured approach called CRAFT has the best evidence. In an analysis of trials it brought about two-thirds of reluctant people into care, usually after the family member had attended four to six sessions.

  • It got roughly three times as many people into care as referral to Al-Anon or Nar-Anon, and twice as many as another established family program
  • Family members' own wellbeing improved whichever approach they used
  • The evidence covers substance use in general, not cannabis specifically
  • Look for a therapist trained in CRAFT

Sources: Roozen et al. 2010

Where to get help

These US services are free and confidential, and open all day, every day. Details were checked on November 14, 2026.

  • 988 Suicide & Crisis Lifeline: call or text 988, or chat at 988lifeline.org
  • SAMHSA National Helpline: 1-800-662-4357, for referrals to local services, in English and Spanish
  • FindTreatment.gov: SAMHSA's confidential search for providers near you
  • In an emergency, call 911

Sources 25

  1. Brezing, C. A., et al. Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder. The American Journal on Addictions, 27(2), pp. 101-107 (2018) doi:10.1111/ajad.12660
  2. Hser, Y.-I., et al. Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. Journal of Substance Abuse Treatment, 81, pp. 53-58 (2017) doi:10.1016/j.jsat.2017.07.012
  3. Atkin, T. B., et al. Beyond abstinence: Redefining success in cannabis use disorder treatment. Addiction (2026) doi:10.1111/add.70517
  4. Fischer, B., et al. Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. International Journal of Drug Policy, 99, 103381 (2022) doi:10.1016/j.drugpo.2021.103381
  5. Halicka, M., et al. Effectiveness and safety of psychosocial interventions for the treatment of cannabis use disorder: A systematic review and meta-analysis. Addiction, 120(11), pp. 2181-2201 (2025) doi:10.1111/add.70084
  6. Gates, P. J., et al. Psychosocial interventions for cannabis use disorder. Cochrane Database of Systematic Reviews (2016) doi:10.1002/14651858.CD005336.pub4
  7. Marijuana Treatment Project Research Group Brief treatments for cannabis dependence: findings from a randomized multisite trial. Journal of Consulting and Clinical Psychology, 72(3), pp. 455-466 (2004) doi:10.1037/0022-006X.72.3.455
  8. Connor, J. P., et al. Cannabis use and cannabis use disorder. Nature Reviews Disease Primers, 7(1) (2021) doi:10.1038/s41572-021-00247-4
  9. Lima, M. G., et al. Contingency Management for Cannabis Use Disorder Treatment. European Addiction Research, 30(5), pp. 321-338 (2024) doi:10.1159/000540193
  10. Spiga, F., et al. Pharmacotherapies for cannabis use disorder. Cochrane Database of Systematic Reviews, 2025(9) (2025) doi:10.1002/14651858.CD008940.pub4
  11. Connor, J. P., et al. Clinical management of cannabis withdrawal. Addiction, 117(7), pp. 2075-2095 (2022) doi:10.1111/add.15743
  12. Freeman, T. P., et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. The Lancet Psychiatry, 7(10), pp. 865-874 (2020) doi:10.1016/S2215-0366(20)30290-X
  13. Lintzeris, N., et al. Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial. JAMA Internal Medicine, 179(9), 1242 (2019) doi:10.1001/jamainternmed.2019.1993
  14. Gray, K. M., et al. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug and Alcohol Dependence, 177, pp. 249-257 (2017) doi:10.1016/j.drugalcdep.2017.04.020
  15. Kondo, K. K., et al. Pharmacotherapy for the Treatment of Cannabis Use Disorder: A Systematic Review. Annals of Internal Medicine, 172(6), pp. 398-412 (2020) doi:10.7326/M19-1105
  16. Côté, J., et al. Digital Interventions for Recreational Cannabis Use Among Young Adults: Systematic Review, Meta-Analysis, and Behavior Change Technique Analysis of Randomized Controlled Studies. Journal of Medical Internet Research, 26, e55031 (2024) doi:10.2196/55031
  17. Boumparis, N., et al. Short- and long-term effects of digital prevention and treatment interventions for cannabis use reduction: A systematic review and meta-analysis. Drug and Alcohol Dependence, 200, pp. 82-94 (2019) doi:10.1016/j.drugalcdep.2019.03.016
  18. Fontana, T. J. K., et al. Feasibility and utility of a structured guide for cannabis tolerance breaks in young adults. Journal of American College Health, 73(1), pp. 5-9 (2025) doi:10.1080/07448481.2022.2155061
  19. Sorensen, C. J., et al. Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review. Journal of Medical Toxicology, 13(1), pp. 71-87 (2017) doi:10.1007/s13181-016-0595-z
  20. Habboushe, J., et al. The Prevalence of Cannabinoid Hyperemesis Syndrome Among Regular Marijuana Smokers in an Urban Public Hospital. Basic & Clinical Pharmacology & Toxicology, 122(6), pp. 660-662 (2018) doi:10.1111/bcpt.12962
  21. Marconi, A., et al. Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. Schizophrenia Bulletin, 42(5), pp. 1262-1269 (2016) doi:10.1093/schbul/sbw003
  22. Di Forti, M., et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. The Lancet Psychiatry, 6(5), pp. 427-436 (2019) doi:10.1016/S2215-0366(19)30048-3
  23. Chesney, E., et al. Psychosis associated with cannabis withdrawal: systematic review and case series. The British Journal of Psychiatry, 226(5), pp. 297-308 (2025) doi:10.1192/bjp.2024.175
  24. American College of Obstetricians and Gynecologists ACOG Clinical Consensus No. 10: Cannabis Use During Pregnancy and Lactation. Obstetrics & Gynecology, 146(4), pp. 600-611 (2025) doi:10.1097/AOG.0000000000006053
  25. Roozen, H. G., et al. Community reinforcement and family training: an effective option to engage treatment-resistant substance-abusing individuals in treatment. Addiction, 105(10), pp. 1729-1738 (2010) doi:10.1111/j.1360-0443.2010.03016.x